Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-76

I think there was a massive rush to acquire Azer-Cel, not only for the stage they were at because an NDA would have been done but for the synergy with Oncarlytics. It’s like Groundhog Day with the CF33 raise and once investors understood the reason, they were over the moon. It takes time to do clinical trials, our stock has been mauled on the ASX-200, some of us are still standing.

This potentially may be the first Allogenic CAR-T approved on a potential Registrational trial - IMU now own the IP (as opposed to autologous CAR-T). Match that up with solid tumours & Oncarlytics…

Looks like we’ve got though a lot of the hard yards now especially with the FDA involved. Looking forward to more news & IMU are very good at giving clarity via webinars etc. Take the time to listen, well worth it.